Race Oncology Receives human ethics approval for Zantrene trialA
- Race Oncology (RAC) has received human ethics approval for its clinical trial of Zantrene in patients with AML and MDS
- All required documents have been submitted with approval expected within four to eight weeks
- The trial is expected to take between 36 to 40 months to complete with treatment to begin once approval is obtained
- Currently, there are no approved treatments for individuals with extramedullary AML as it is difficult to treat
- MDS are a group of blood cancers that affect the production of normal blood cells in the bone marrow
- Race has ended the day a slight 0.72 per cent in the red with shares trading at $2.75
